News and Media

For press releases:

2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999

Receive E-mail alerts

Subscribe to RSS feeds

December 27, 2005

FDA Approves MedImmune's State-of-the-Art Influenza Vaccine Manufacturing Facility

December 15, 2005

MedImmune Completes Enrollment in Phase 3 Study Comparing Numax(TM) to Synagis(R)

December 14, 2005

MedImmune and Biota Announce Collaboration to Develop New Therapies for RSV Infection

December 12, 2005

Preliminary Data from CAIV-T Pivotal Phase 3 Trial Demonstrate Clinical Efficacy Over Flu Shot in Head-to-Head Influenza Study

December 8, 2005

MedImmune Licensing New Antibody-Enhancing Technologies to Further Strengthen its Development-Stage Pipeline

December 8, 2005

MedImmune Expands Oncology Pipeline with Increased Focus on Eph Proteins as Potential Target for New Cancer Therapies

December 7, 2005

MedImmune Expands Patent Estate for Reverse Genetics with New Rights from Mount Sinai School of Medicine

December 6, 2005

MedImmune Continues to Build Strength and Depth in Management Team

November 16, 2005

MedImmune to Build New Biologics Manufacturing Facility in Frederick, Maryland

October 20, 2005

MedImmune Further Expands Oncology Pipeline With New Target Based on Innovative Technology From Avidia

October 20, 2005

MedImmune Reports 2005 Third Quarter and Nine-Month Financial Results

October 17, 2005

MedImmune Completes Cellective Acquisition

October 13, 2005

MedImmune and Medarex Announce Filing of Investigational New Drug Application for Monoclonal Antibody for the Treatment of Lupus

October 12, 2005

MedImmune Named One Of Maryland's Fastest Growing Technology Companies In Deloitte Technology Fast 50 Program

September 28, 2005

MedImmune to Collaborate With National Institutes of Health to Develop Pandemic Influenza Vaccine

September 26, 2005

Cancer Target Collaboration Agreement Signed Between MedImmune and Georgetown University

September 19, 2005

MedImmune Submits Refrigerator-Stable Formulation of FluMist(R) to FDA for Approval in Healthy Individuals 5 to 49 Years of Age

September 16, 2005

MedImmune's General Counsel Named a 'Top Washington Lawyer'

September 14, 2005

MedImmune to Acquire Cellective Therapeutics, Inc.

September 8, 2005

MedImmune and VasGene Therapeutics Announce Collaboration to Develop Monoclonal Antibodies Targeting Cancer

September 8, 2005

MedImmune Expands Executive Ranks With Four New Vice Presidents

September 1, 2005

CDC's Recommended Influenza Prioritization Schedule Highlights FluMist(R) as an Option to Protect Healthy People 5-49 Years of Age

September 1, 2005

MedImmune's Phase 1 Numax(TM) Study Shows Potential to Reduce RSV Disease in Upper Airway of Children

August 31, 2005

MedImmune Amends U.S. Co-Promotion Agreement for Synagis(R) With Abbott

August 29, 2005

MedImmune Licenses Worldwide Rights for Anti-Staphylococcal Antibody Program From GlaxoSmithKline

July 21, 2005

MedImmune Reports 2005 Second Quarter and Six-Month Financial Results

June 20, 2005

MedImmune and Avalon Pharmaceuticals Announce Collaboration to Discover Small Molecule Therapeutic Drugs for Inflammatory Diseases

June 16, 2005

Preliminary Results of Phase 3 Bridging Study Show Comparable Immunogenicity of Frozen FluMist(R) and Investigational Liquid Formulation

May 25, 2005

Preclinical Data Support Link Between IL-9 and Airway Hyperresponsiveness Associated With Asthma

May 18, 2005

MedImmune and Pediatric Infectious Diseases Society Present First Annual 'MedImmune Career Development Award' to Stanford University Physician

May 17, 2005

MedImmune Awards Fellowship Grants in Pediatric Research Totaling $210,000

May 17, 2005

Preliminary Phase 1 Data Show MedImmune's Siplizumab Well Tolerated in CD2-Positive Lymphoma and Leukemia Patients

May 14, 2005

Data From Several Studies of Medimmune's Intranasal Influenza Vaccines Support Broad Protection Against Influenza

May 14, 2005

Additional Safety Data Presented at PAS Annual Meeting on MedImmune's Next-Generation Product to Help Prevent RSV Disease in High-Risk Infants

May 14, 2005

Preliminary Analysis of Phase 2 Study Shows 53 Percent of Patients With Stage IV Metastatic Melanoma Survive One-Year Mark When Treated With Vitaxin(R)

April 21, 2005

MedImmune Reports Financial Results for First Quarter 2005

April 15, 2005

MedImmune Begins Dosing in Phase 1 Clinical Trial for Nasally Delivered Vaccine Designed to Help Prevent Common Childhood Respiratory Viral Diseases

April 4, 2005

MedImmune Announces Addition of George M. Milne, Jr., Ph.D. to Board of Directors

March 22, 2005

Montgomery Blair High School Senior Receives Newly Created Science Award From MedImmune

February 28, 2005

MedImmune Expands Ex-U.S. Distribution Agreement with Abbott for Monoclonal Antibodies Against RSV

February 22, 2005

MedImmune Announces New Senior Appointment and Five Executive Promotions

February 22, 2005

MedImmune Allocates an Additional $100 Million to Venture Capital Fund

February 3, 2005

MedImmune's Product Sales Surpass $1 Billion for First Time

February 2, 2005

MedImmune Amends Agreement for Cervical Cancer Vaccine With Glaxosmithkline

January 20, 2005

MedImmune Files Investigational New Drug Application for Nasally Delivered RSV/PIV-3 Vaccine

January 11, 2005

MedImmune Updates Investors at JPMorgan Healthcare Conference